---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094848"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-08-12T20:01:42+00:00"
generated_at: "2026-08-12T20:03:36.640288+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports $11.2M cash; going concern doubt persists

## Summary
- Preliminary cash and cash equivalents of $11.2M as of June 30, 2026 (unaudited).
- Net loss of $62.4M in FY2025; revenue of $1.4M from LYTENAVA sales in Germany/UK.
- Going concern: cash only sufficient into September 2026; need substantial additional capital.
- $19.8M outstanding under Atlas Sciences note due June 2027; 7.5% exit fee on redemptions.
- Terminated ATM prospectus supplement with H.C. Wainwright on Aug 10, 2026; agreement remains.

## SEC filing metadata
- accession: 0001104659-26-094848
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-08-12T20:01:42+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/0001104659-26-094848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/tm2622278d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094848
- JSON: https://secwatch.observer/filing/0001104659-26-094848.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.